Tests extra support for children with high-risk neuroblastoma from low-income families
Tests added RISE support alongside usual care for low-income children with neuroblastoma.
Key facts
- Who runs it
- Dana-Farber Cancer Institute
- Where
- Atlanta, Aurora, Boston, Cincinnati, Dallas, Hartford, New York, Philadelphia, and Seattle, United StatesSee the 9 sites
- Trial code
- Registry title
- Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Status
- Recruiting
- People taking part
- 84 people, planned
- Started
- 30 Apr 2025
- Expected to end
- 1 Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- RISE Intervention
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with newly diagnosed high-risk neuroblastoma whose families have a low income. It tests an income support program added to usual supportive care.
- Age
- 0 to 17 years at the time of consent
- Sex
- All sexes can join
- Disease stage
- Newly diagnosed high-risk neuroblastoma
- Earlier treatment
- Child has started cancer treatment at the study site but has not yet started Induction Cycle 3
Main reasons for not taking part
- Foreign national family receiving care as an Embassy-pay patient
- Child or household member receiving SSI
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patient cohort: The randomized Phase II multi-center RISE intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. Poverty will be a priori defined as parent-reported low-income (<200% Federal Poverty Level). Children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances
- Patient newly diagnosed with high-risk neuroblastoma
- Patient has established care at study site and initiated cancer-directed therapy
- Patient has not yet initiated Induction Cycle 3
- Patient aged 0-17 years at the time of consent
- Parent/guardian screened positive for self-reported low-income (<200% Federal Poverty) *
- Family primary residence in MA, PA, IL, CA, WA, CT, GA, WI and OH
- Both patients co-enrolled on ANBL2131 or those receiving standard of care therapy at their center are eligible to participate
- Patients of all languages are eligible to participate
Who cannot take part
- Foreign national family receiving care as an Embassy-pay patient
- Child or household member receiving SSI
Where in United States
- Children's Healthcare of AtlantaAtlanta, United StatesContact: Thomas Cash, MDTaking people
- Children's Hospital ColoradoAurora, United StatesContact: Katherine Lind, MDTaking people
- Dana-Farber Cancer InstituteBoston, United StatesContact: Kira Bona, MD, MPHTaking people
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Katherine Somers, MDTaking people
- University of Texas Southwestern Medical CenterDallas, United StatesContact: Puja Umaretiya, MDTaking people
- Connecticut Children's Medical CenterHartford, United StatesContact: Andrea Orsey, MD, MSCETaking people
- Columbia University Medical CenterNew York, United StatesContact: Melissa Beauchemin, MDTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Rochelle Bagatell, MDTaking people
- Seattle Children's HospitalSeattle, United StatesContact: Anurekha Hall, MDTaking people
About the trial
What the trial wants to find out
The goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (Pediatric Resource Intervention to Support Equity [Pediatric RISE]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes.
Read full original descriptionShow less
Participants will be randomized to receive one of the following for 6-months:
* Usual supportive care alone or * Usual supportive care plus Pediatric RISE
The 2 groups in the trial
- Arm 1: RISE Intervention + Usual Supportive CareTreatment being tested
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and Household Material Hardship (HMH) severity score. Participant parents/guardians will complete: * Orientation visit in-person, by phone, or virtually with survey * Access to usual supportive oncology care comprised of social workers, resource specialists and/or psychosocial oncology teams * Meeting with a benefits counselor by phone or virtually and follow up meetings if needed * Fixed amount of cash assistance 2x monthly * 3 months survey * 6 month survey
Treatment: RISE Intervention
- Arm 2: Usual Supportive CareNo study treatment, for comparison
Participants will be randomized in a 1:1 ratio and stratified according to treatment group and HMH severity score. Participant parents/guardians will complete: * Orientation visit in-person, by phone, or virtually with survey * Access to usual supportive oncology care comprised of social workers, resource specialists and/or psychosocial oncology teams * 3 month survey * 6 month survey
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Phase II Trial Evaluation of the Addition of the Resource Intervention to Support Equity (RISE) to Usual Supportive Care for Children With Newly Diagnosed High-Risk Neuroblastoma
- Plain-language title
- Tests extra support for children with high-risk neuroblastoma from low-income familiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 13 November 2026